Advertisement

Experience with Leuprorelin Acetate as a Depot Formulation for Prostate Cancer in a Long-Term Follow-Up Study

  • A. O’Brien
  • R. Grainger
  • M. R. Butler
Conference paper
  • 12 Downloads

Abstract

Carcinoma of the prostate is a significant cause of morbidity and mortality in men aged 60 years and over. With the increasing life expectancy and improved screening, the incidence and prevalence of prostatic carcinoma have increased, particularly in developed countries. The incidence of newly diagnosed cases is the highest in the USA (75 per 100 000) and ranges from 10 to 40 per 100 000 in Europe [14]. In 1975, prostatic carcinoma was the second most common male cancer in industrialised countries and the third most frequent cause of death from cancer in men, accounting for about 10% of such deaths [1]. While the true prevalence of prostatic carcinoma is unknown, it has been estimated to range from 5% to 40% of men over 50 years and in a series of autopsies has been as high as 67% of men over 80 years old [3]. Even though the great majority of cases are not diagnosed, prostatic carcinoma must be the most prevalent carcinoma in men. The effective management of such a dominant carcinoma can only become increasingly important in the future.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Debre B, Geraud M, FlamT, Steg A (1990) Epidemiology of prostatic cancer. J Int Med Res 18 [Suppl 1]: 3–7PubMedGoogle Scholar
  2. 2.
    Di Silvero F (1975) Histological type of tumor and hormone dependence. In: Bracci U, Di Silvero (eds) Hormonal therapy in prostate cancer. Cofese Edizioni, Palermo, pp 47–58Google Scholar
  3. 3.
    Franks LM (1954) Latent carcinoma of the prostate. J Pathol Bacteriol 68: 603–616PubMedCrossRefGoogle Scholar
  4. 4.
    Huggins C, Scott WW (1945) Bilateral adrenalectomy in prostatic cancer. Clinical features and urinary excretion of 17-ketosteroids and estrogen. Ann Surg 122: 1031–1040CrossRefGoogle Scholar
  5. 5.
    Huggins C, Stevens RE, Hodges CV (1941) Studies on prostatic cancer II. The effects of castration on advanced carcinoma of prostatic gland. Arch Surg 43: 209–223Google Scholar
  6. 6.
    Leuprolide Study Group (1984) Leuprolide versus diethylstilboestrol for metastatic prostate cancer. N Engl J Med 311: 1281–1286CrossRefGoogle Scholar
  7. 7.
    Mazzei T, Mini E, Rizzo M, Periti P (1990) Human pharmacokinetic and pharmacodynamic profiles of leuprorelin acetate depot in prostatic cancer patients. J Int Med Res 18 [Suppl 1]: 42–56PubMedGoogle Scholar
  8. 8.
    Newling DWW, Dennis L, Mahler C, Debruyne FMJ, Lunglmayr G, Robinson MRG, Richards B (1987) Clinical and endocrinological results with a biodegradeable depot LHRH analogue (Zoladex) in the management of advanced prostatic cancer. In: Chisholm GD (ed) Zoladex: a new treatment for prostatic cancer. Society of Medicine London, pp 17–24 (International Congress and Symposium Series number 125 )Google Scholar
  9. 9.
    Rizzo M, Mazzei T, Mini E, Bartoletti R, Periti P (1990) Leuprorelin acetate depot in advanced prostatic cancer: a phase II multicentre trial. J Int Med Res 18 [Suppl 1]: 114–125PubMedGoogle Scholar
  10. 10.
    Schmidt JD, Scott W, Gibbons R (1980) Chemotherapy programs of the National Prostatic Cancer Project. Cancer 45: 1937–1946PubMedGoogle Scholar
  11. 11.
    Sharifi R, Soloway M, and the Leuprolide Study Group (1990) Clinical study of leuprolide depot formulation in the treatment of advanced prostatic carcinoma. J Urol 143 (1): 68–71PubMedGoogle Scholar
  12. 12.
    Toguchi H (1990) Pharmaceutical manipulation of leuprorelin acetate to improve clinical performance. J Int Med Res 18 [Suppl 1]: 35–41PubMedGoogle Scholar
  13. 13.
    Veterans Administrative Collaborative Urological Research Group (1967) Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 124: 1011–1017Google Scholar
  14. 14.
    Waterhouse J, Shanmugaratham K, Muir C, Powell J (1982) Cancer incidence in five continents, vol IV. IARC, Lyon (IARC Scientific Publications no. 42 )Google Scholar
  15. 15.
    World Health Organization (1979)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • A. O’Brien
  • R. Grainger
  • M. R. Butler

There are no affiliations available

Personalised recommendations